Esperion Therapeutics Inc. (ESPR) Income Statement Analysis - Revenue, Earnings & Profitability Metrics - Stocknear
Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Start Trial

    Esperion Therapeutics Inc...

    NASDAQ: ESPR · Real-Time Price · USD
    2.53
    0.10 (4.12%)
    At close: Sep 04, 2025, 3:59 PM
    2.52
    -0.40%
    Pre-market: Sep 05, 2025, 08:13 AM EDT

    Esperion Therapeutics Income Statement

    Financials in USD. Fiscal year is January - December.

    undefined peaked at n/a in undefined and hit its lowest at n/a in undefined. Over the past five years, it has declined by undefined%.

    Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
    Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
    Revenue
    		 332.31M 116.33M 75.47M 78.45M
    Cost of Revenue
    		 68.6M 43.27M 26.97M 14.22M
    Gross Profit
    		 263.71M 73.07M 48.51M 64.23M
    Operating Income
    		 54.4M -155.56M -179.5M -226.73M
    Interest Income
    		 n/a n/a n/a 112K
    Pretax Income
    		 -51.74M -209.25M -233.66M -269.11M
    Net Income
    		 -51.74M -209.25M -287.82M -318.82M
    Selling & General & Admin
    		 163.07M 142.52M 109.08M 184.99M
    Research & Development
    		 46.24M 86.11M 118.93M 105.97M
    Other Expenses
    		 n/a n/a n/a n/a
    Operating Expenses
    		 209.31M 228.63M 228.01M 290.96M
    Interest Expense
    		 59.25M 58.98M 56.81M 46.35M
    Selling & Marketing Expenses
    		 25.5M n/a 11.3M 13.7M
    Cost & Expenses
    		 277.91M 271.9M 254.98M 305.18M
    Income Tax Expense
    		 n/a n/a 54.16M 49.72M
    Shares Outstanding (Basic)
    		 187.18M 103.11M 66.41M 28.9M
    Shares Outstanding (Diluted)
    		 187.18M 103.11M 66.41M 28.9M
    EPS (Basic)
    		 -0.28 -2.03 -4.33 -11.03
    EPS (Diluted)
    		 -0.28 -2.03 -4.33 -11.03
    EBITDA
    		 7.57M -150.11M -176.35M -222.14M
    EBIT
    		 7.51M -150.27M -176.85M -222.75M
    Depreciation & Amortization
    		 63K 164K 500K 612K

    Add to Watchlist